Mapinastine is a biochemical assay reagent.

MAP3K14-IN-1 (Compound 173) is a MAP3K14 (NIK kinase) inhibitor with an IC50 of 1.8 nM. MAP3K14-IN-1 inhibits the autophosphorylation of MAP3K14 kinase. MAP3K14-IN-1 reduces the level of phosphorylated IKKα in cancer cells. MAP3K14-IN-1 inhibits the proliferation of multiple myeloma cells. MAP3K14-IN-1 can be used in research related to multiple myeloma.

MAO-B-IN-53 is a human monoamine oxidase B (hMAO-B) inhibitor with an IC50 of 0.066 μM. MAO-B-IN-53 exhibits mixed reversible inhibition, binds stably to the hMAO-B active site, and shows high selectivity over hMAO-A. MAO-B-IN-53 acts as a neuroprotective agent, protects against 6-OHDA-induced damage, and exhibits low neurotoxicity in neuroblastoma cells. MAO-B-IN-53 can be used for the research of Parkinson's disease.

MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. MAO-B-IN-50 shows good inhibitory effects on the aggregation of Aβ40/42 and Tau proteins, with overall IC50 values around 1 μM. MAO-B-IN-50 exhibits potent and selective AChE inhibition (IC50 = 1.78 μM). MAO-B-IN-50 can be used in the research of Alzheimer's disease.

MAO-B-IN-49 is a selective and reversible MAO-B inhibitor (IC50 of 1 nM for human MAO-B). MAO-B-IN-49 shows much higher selectivity for MAO-B than for MAO-A (IC50 = 633.9 μM). MAO-B-IN-49 can reduce ROS production induced by Lipopolysaccharides (LPS) in HT22 cells. MAO-B-IN-49 demonstrates substantial neuroprotective properties and significantly improves motor dysfunction in MPTP-induced mouse models of Parkinson’s disease (PD). MAO-B-IN-49 can be used for the study of PD.

Man-GIcNAc-oxazoline (compound 6) is an N-acetylglucosamine (GlcNAc) and azide-modified disaccharide that can be used to label antibodies. Man-GIcNAc-oxazoline can be synthesized as an ADC via click chemistry.

Mal-Pip-ValCit-PAB-AZ7550 is a prodrug of EGFR inhibitor. Mal-Pip-ValCit-PAB-AZ7550 selectively binds covalently to albumin via its maleimide moiety. Mal-Pip-ValCit-PAB-AZ7550 exhibits potent in vivo anticancer activity in non-small cell lung cancer xenograft models. Mal-Pip-ValCit-PAB-AZ7550 can be used in research related to non-small cell lung cancer.

Mal-PEG-NHS ester (MW 2000) is a PEG linker, can be used to link lipoteichoic acid (LTA) and CpG DNA fragments to synthesis CpG-TA Heterodiners. Mal-PEG-NHS ester (MW 2000) can be used for immune stimulation research.

Mal-PEG2-Val-Arg-PABC-OMe-Eribulin (Compound L-1) is a drug-linker conjugate composed of O-Me Eribulin and the linker Mal-PEG2-Val-Cit-PAB-OH. Mal-PEG2-Val-Arg-PABC-OMe-Eribulin can be used to synthesize anti-HER3/MET antibody-drug conjugates (ADCs).

Mal-PEG2-azide is a PEG ADC linker, can be used for ADC synthesis.

Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid .

Mafoprazine methanesulfonate is a phenylpiperazine derivative with variable affinities for neuronal receptors. It may exert its antipsychotic effects primarily through D2 receptor blockade and α-adrenergic activity, and may increase the activity of dopamine metabolites.

M4K-2009 is an BBB-penetrant inhibitor of ALK2 with an IC50 of 13 nM. M4K-2009 is an analogue of LDN-214117. M4K-2009 is also active against the hERG potassium channel.

Lysyl-phenylalanyl-lysine (Compound KFK) is a tripeptide and belongs to the peptide segments related to thrombospondin-1 (TSP-1). Lysyl-phenylalanyl-lysine can activate LAP-TGF-β1 and release active TGF-β1, thereby inhibiting abnormal expression of MMP. Lysyl-phenylalanyl-lysine can be used for research on skin aging-related diseases and poor wound healing.

Lys-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader with DC50 values of 1.32 and 19.66 μM for H3122 (EML4-ALK) and H1975 (EGFR-L858R/T790M) cells, respectively. Lys-PEG3-BA hinders proliferation via rewiring the ubiquitin- proteasome system in vitro. Lys-PEG3-BA can be used for non-small cell lung cancer research.

Lyso iGB3 is a glycosphingolipid.

Lycorine methiodide (N-Methyllycorine iodide) is a derivative of Lycorine. Lycorine methiodide exhibits no significant in vitro antitumor activity against A549, OE21, Hs683, U373, SKMEL, and B16F10 cell lines, with all IC50 values greater than 10 μM.

LY-73497 is a Phenethylthiazolythioureas derivative. LY-73497 has anti-HIV-1 activity.

LY-33169 is an antitumor agent. LY-33169 had selective cytotoxicity against Colon Adenocarcinoma-38, Human Colon-116, Human Prostate LNCaP, and Human Breast WSU-Br-1 cells.

LY3295668 (AK-01) erbumine is a highly specific and orally active inhibitor of Aurora-A kinase with a Ki values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 erbumine can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 erbumine avoids the formation of polyploids related to AurB inhibition. LY3295668 erbumine can be used for the study of small cell lung cancer.

LY 300168 (GYKI 53655) is a non-competitive, blood-brain-barrier permeable AMPA receptor antagonist. LY 300168 attenuates hippocampal injury. LY 300168 blocks the sound-induced clonic and tonic convulsions.

LY 78335 (DCMB) is a brain-penetrant phenylethanolamine-N-methyltransferase (PNMT) inhibitor with a Ki of 0.09 μM. LY 78335 acts as an α₂-adrenoceptor inhibitor with an IC50 of 10 μM. LY 78335 increases spontaneous locomotor activity in rats. LY 78335 increases extracellular concentration of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rat hypothalamus. LY 78335 prevents growth hormone (GH) secretion in rats. LY 78335 can be used for the research of depression.

LXR modulator-1 (Compound 21/3) is a LXR modulator with an EC50 of less than 100 nM. LXR modulator-1 can be used for studying LXR-mediated diseases such as non-alcoholic fatty liver disease.

LUF7996 is a CCR2 PROTAC Degrader degrading CCR2 with DC50 = 2.6 μM. LUF7996 demonstrates engagement of both and the E3 ligase cereblon and displays sustain and concentration-dependent degradation of CCR2. LUF7996 reliance on the lysosomal pathway to induce CCR2 degradation. LUF7996 efficiently inhibits monocyte migration in virto. (Pink: CCR2 ligand ; Blue: Cereblon ligand ; Black: linker).

LSD1-IN-49 hydrochloride (Compound (±) 1) is an irreversible LSD1/KDM1A inhibitor with an IC50 of 29 nM against hLSD1. LSD1-IN-49 hydrochloride irreversibly inhibits the enzymatic activity of LSD1 by forming an adduct with flavin adenine dinucleotide (FAD) in the binding pocket of LSD1. LSD1-IN-49 hydrochloride is applicable to research related to schizophrenia, autism spectrum disorder and Huntington's disease.

LSD1-IN-49 is a Lysine-specific demethylase 1 (LSD1/KDM1A) inhibitor with a human IC50 of 29 nM. LSD1-IN-49 irreversibly inhibits LSD1 enzyme activity by forming an adduct with the flavin adenine dinucleotide (FAD) cofactor of LSD1. LSD1-IN-49 can be used as a lead compound for the development of LSD1-targeted PET imaging agents for the brain.

LSD1-IN-48 is a tranylcypromine-pyrimidine derivative and selective LSD1 inhibitor with a human IC50 of 7.87 nM. LSD1-IN-48 increases H3K4me1/2 histone methylation levels. LSD1-IN-48 induces apoptosis, upregulates CD86, downregulates SOX2 and CD44, inhibits proliferation in cancer cells. LSD1-IN-48 can be used for the research of acute myeloid leukemia.

LSD1-IN-46 is a potent and orally active Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 0.082 μM. LSD1-IN-46 interrupts the β-catenin-mediated transcriptional program, thereby suppressing the stemness of gastric cancer cells. LSD1-IN-46 exhibits strong anti-tumor activity. LSD1-IN-46 can be used for the research of gastric cancer.

LP-371-p is a lipid that can specifically and efficiently deliver oligonucleotide compounds to the fat tissues in the body (especially fat cells). LP-371-p can be used in research on diseases related to fat, such as obesity and type 2 diabetes.

LP293-p is a lipid with activated ester groups, which can be used for the synthesis of ATXN2 RNAi. LP293-p can be utilized to enhance the targeting of the central nervous system (CNS).